Contentious COVID-19 patents: UPC revokes remdesivir patent
On 4th May, the UPC revoked the ‘remdesivir’ anti-viral drug unitary patent owned by Chinese research institute AMMS and rejected all limitations proposed by the patentee (case ID… read more…
G 1/25 “Hydroponics”: Enlarged Board hears challenge to EPO description amendment practice
Users of the European patent system will be familiar with the EPO’s long-standing practice of requiring the description to be brought into line with amended claims, both before grant and in… read more…
Mathys & Squire featured in World Intellectual Property Review Leaders 2026
Mathys & Squire is proud to share that a selection of our Partners have been featured in the 2026 edition of World Intellectual Property Review (WIPR) Leaders Partners Claire Breheny, Anna… read more…
Mathys & Squire will be at Bio Integrates 2026
Mathys & Squire will be at Bio Integrates 2026 in Bloomsbury, London on the 14th of May Managing Associate Lionel Newton will be attending Bio Integrates 2026, hosted by Life Science… read more…
Mathys & Squire will be at Vitafoods Europe 2026
Mathys & Squire will be at Vitafoods Europe 2026 in Barcelona, Spain from the 5th to the 7th of May Partner Michael Stott will be attending Vitafoods Europe 2026 in Barcelona and will be part… read more…
Mathys & Squire will be at the INTA 2026 Annual Meeting
Mathys & Squire will be at the INTA 2026 Annual Meeting in London, United Kingdom from the 2nd to the 6th of May Partners Chris Hamer, Andreas Wietzke and Matthias Brittinger from our… read more…
